News >

Experts Explain Impact of Trastuzumab Deruxtecan Approval in HER2+ Breast Cancer

Jessica Hergert
Published: Thursday, Mar 26, 2020

Sara A. Hurvitz, MD, an associate professor at the David Geffen School of Medicine and medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit at the University of California, Los Angeles

Sara A. Hurvitz, MD

The recent approval of the novel antibody–drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) has added a remarkable asset to the armamentarium in HER2-positive metastatic breast cancer, said Sara A. Hurvitz, MD. However, questions remain regarding sequencing strategies with the agent and concerns over the potential risk of interstitial lung disease (ILD).

Several other experts provided their thoughts on the ADC including:
  • Oludamilola (Lola) A. Olajide, MD, an adjunct professor and medical oncologist at the Rex Cancer Center of UNC Health
  • Elisa Krill-Jackson, MD, the associate director of community outreach for women's health at the Sylvester Cancer Center of the University of Miami Health System
  • Forrest Thompson, MD, a hematologist and medical oncologist at the Levine Cancer Institute of Atrium Health
In an interview with OncLive, these faculty voiced their opinion on the clinical utility of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer.

 
Elisa Krill-Jackson, MD, the associate director of community outreach for women's health at the Sylvester Cancer Center of the University of Miami Health System

Elisa Krill-Jackson, MD

Historically, patients who progress on T-DM1 received a hodgepodge of multiple treatments, none of which seem to keep patients in long-term remission.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x